Optimization of nanoliposomes encapsulation Avastin using an experimental design

Ocular drug delivery is one the most challenging fields for pharmacologists. Avastin (Bevacizumab) a synthetic and whole humanized monoclonal antibody which binds all isoforms of vascular endothelial growth factor (VEGF), is used for the treatment of different ocular diseases which are caused by abnormal neovascularization. The short halflife of the drug in vitreous necessitates frequent drug administration so employing controlled-release drug delivery systems such as nanoliposomes has been particularly noticed. The goal in the present experiment was optimizing and evaluating liposomal encapsulation efficiency of Avastin in nanoliposome. Using the dehydration-rehydration Method, Bevacizumab (Avastin) was encapsulated into liposomes (Avs-NLP). Dynamic light scattering analyzing revealed that size of Avs-NLP was 139.9 nm. The effect of some independent variables including DPPC (1, 2-dipalmitoyl-snglycerophosphocholine), cholesterol, and Avastin concentrations and freeze/thawing cycles on entrapment efficiency % (DEE) were evaluated utilizing response surface methodology (RSM). Optimal conditions for the maximum DEE (39.9%) was obtained with 1.6 mg Avastin, 2 mg DPPC, 0.37mg cholesterol and 7 freeze/thawing cycles. The optimization of the formulations for valuable and expensive drugs is essential to have the maximum encapsulation efficiency and the minimum experiments

کلیدواژه ها:

Avastin (Bevacizumab) ، Nanoliposome ، Ocular drug delivery